Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aditxt Inc (ADTX)

Aditxt Inc (ADTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,053
  • Shares Outstanding, K 731
  • Annual Sales, $ 130 K
  • Annual Income, $ -34,450 K
  • EBIT $ -21 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.43
  • Price/Sales 12.23
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +9.23%
on 12/15/25
4.8519 -70.73%
on 11/17/25
-3.4196 (-70.66%)
since 11/14/25
3-Month
1.3000 +9.23%
on 12/15/25
123.1700 -98.85%
on 09/23/25
-116.0887 (-98.79%)
since 09/16/25
52-Week
1.3000 +9.23%
on 12/15/25
8,633.1992 -99.98%
on 12/17/24
-8,603.5303 (-99.98%)
since 12/16/24

Most Recent Stories

More News
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

Aditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals

ADTX : 1.4200 (-1.39%)
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of...

ADTX : 1.4200 (-1.39%)
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-invasive alternative to surgical diagnosis for endometriosis

ADTX : 1.4200 (-1.39%)
Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt --

EVFM : 0.0101 (-9.01%)
ADTX : 1.4200 (-1.39%)
Aditxt Appoints New General Counsel and Officer

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

ADTX : 1.4200 (-1.39%)
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI ® (lactic acid citric acid and potassium bitartrate) --

EVFM : 0.0101 (-9.01%)
ADTX : 1.4200 (-1.39%)
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

-- Special Meeting to be held on September 26, 2025 --

EVFM : 0.0101 (-9.01%)
ADTX : 1.4200 (-1.39%)
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026

ADTX : 1.4200 (-1.39%)
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives --

EVFM : 0.0101 (-9.01%)
ADTX : 1.4200 (-1.39%)
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Crypto.com to Provide Custody Services for Proposed Aditxt Digital Asset Treasury

ADTX : 1.4200 (-1.39%)

Business Summary

Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.

See More

Key Turning Points

3rd Resistance Point 1.7968
2nd Resistance Point 1.6935
1st Resistance Point 1.5567
Last Price 1.4200
1st Support Level 1.3166
2nd Support Level 1.2133
3rd Support Level 1.0765

See More

52-Week High 8,633.1992
Fibonacci 61.8% 5,335.8135
Fibonacci 50% 4,317.2495
Fibonacci 38.2% 3,298.6855
Last Price 1.4200
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar